Abbonarsi

Is serum gentamicin concentration modified with autologous cell-saved blood transfusion after total knee arthroplasty using tranexamic acid? A randomised control trial - 27/04/21

Doi : 10.1016/j.otsr.2020.102794 
Panagiotis Touzopoulos a, ⁎ , Konstantinos Arvanitidis b, Eirini Filidou b, Konstantinos Tilkeridis c, Michael Karanikas d, George Kolios b, Athanasios Ververidis c
a Department of Orthopaedics, General University Hospital of Alexandroupolis, Alexandroupolis, Greece 
b Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece 
c Department of Orthopaedics, Medical School, Democritus University of Thrace, Alexandroupolis, Greece 
d Department of Surgery, Medical School, Democritus University of Thrace, Alexandroupolis, Greece 

⁎Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Background

Self-transfusion has been proven as an effective management of blood loss after total knee arthroplasty (TKA). Considering that the high local concentration of antibiotic from bone cement is delivered intravenously through the self-transfusion process, systematic toxicity has never been evaluated. In addition, the effectiveness of self-transfusion with the routine concomitant use of other modern blood-salvage strategies, like tranexamic acid, should also be assessed. Therefore, we performed a randomised study to assess: 1) the safety of self-transfusion in TKA by comparing the gentamicin concentrations resulting from the use or not of autologous blood transfusion; 2) the efficacy of self-transfusion in TKA, with the concomitant administration of tranexamic acid.

Hypothesis

Self-transfusion in TKA elevates the serum gentamicin concentration and the potential risk of nephrotoxicity.

Methods

The serum concentration of aminoglycosides was measured in two groups of 20 patients each, after TKA, according to the use of self-transfusion. Hemoglobin, renal function and calculated blood loss were compared at several points in time between groups.

Results

The only time where there was a statistically significant difference in serum gentamicin, was at 48h postoperatively between groups [0.3 ug/mL±0.21, range: 0.15 to 0.72 vs. 0.14ug/mL±0.1, range: 0 to 0.35 (p=0.02)]. There were no significant differences in total blood loss [1341mL±501, range: 830 to 2230 vs. 1263mL±459 range: 840 to 2480 (p=0.67)] and need of allogeneic blood transfusion [3 units vs. 2 units] between groups.

Conclusion

The use of autologous blood transfusion was found to be safe, in terms of nephrotoxicity of aminoglycosides after TKA, but it seemed to be ineffective as a blood salvage strategy, when used concomitantly with the administration of tranexamic acid.

Level of evidence

II; low-powered randomised study.

ClinicalTrials.gov registration number

NCT04505748.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Gentamicin, Self-transfusion, Blood loss, Toxicity, Total knee, Tranexamic acid


Mappa


© 2020  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 107 - N° 3

Articolo 102794- maggio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Blood loss after revision knee arthroplasty is 1.38- to 2.17-fold higher than after primary knee arthroplasty: A retrospective analysis of 898 cases
  • Antonio Klasan, Florian Gerber, Arne Schermuksnies, Sven Edward Putnis, Thomas Neri, Thomas Jan Heyse
| Articolo seguente Articolo seguente
  • Navigated total knee arthroplasty: Retrospective study of 600 continuous cases
  • Jean-Claude Bové, Arnaud Clavé

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.